Drug Trial Radar · NCT06804590
A Study on Efficacy, Safety and Immunogenicity of 9MW0311 in Postmenopausal Women With Osteoporosis
Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
280
Actual
Start
Nov 16, 2024
Primary completion
Apr 24, 2026
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 3, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 50 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a multicenter, randomized, double-blinded, parallel-group Phase III clinical study to compare the clinical efficacy, safety, and immunogenicity of 9MW0311 and Prolia® in Chinese postmenopausal women with osteoporosis at high risk for fracture.
Conditions
- Postmenopausal Women Osteoporosis
Interventions
9MW0311Drug
9MW0311 Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.
Prolia®Drug
Prolia® Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in lumbar spine(LS)-BMD at Week 53 (Month 12)Time frame: Baseline and 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Mabwell (Shanghai) Bioscience Co., Ltd.
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.